CSL's share price has declined by 35% in 2025, influenced by a challenging US healthcare industry and cautious growth prospects. Despite headwinds, UBS sees potential medium-term recovery, especially ...

Some of Australia’s largest blue-chip investors have been caught on the wrong side of one of the year’s most crowded trades after piling into CSL as an alternative to holding a big position in ...

Certainly! Here's the revised description with all links removed: --- Ring use Basic Wire Weaving techniques - How to make handmade jewelry from copper wire by Lan Anh Handmade Can do the same with ...

Nov 18 (Reuters) - Australian biotech firm CSL (CSL.AX), opens new tab said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company announced in August ...

Health editor Michael Smith on CSL’s remarkable story, why investors have fallen out of love with the healthcare giant and what Trump has to do with it. CSL was run like a bureaucracy until 1990 when ...

A profit downgrade caused by Americans shunning vaccines, a pullback of demand in China and a decision to shelve the spin-off of Seqirus sent its share price crashing almost 17 per cent on Tuesday. Mr ...

Alongside the U.S. government’s overhaul of the federal vaccine infrastructure, influenza vaccination rates in the country have plummeted below the expectations of a key player in the space. That ...

A strike is when more than 25 per cent of shareholders are against a company proposal, in this case executive pay, paving the way for a second ballot on whether to spill the board. Shareholders have ...

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...

(Reuters) -Australian biotech CSL on Tuesday delayed its planned vaccine division spin-off and cut earnings forecasts due to a bigger-than-expected decline in U.S. flu vaccination rates, sending its ...